Adults with SBMA have elevated levels of NfL and GFAP, two biomarkers for nerve damage, in their cerebrospinal fluid, a study ...

The company's laboratory-developed test (LDT) for neurofilament light chain (NfL) also gained New York State approval as part of the permitting process.

A recent eGastroenterology review by Professor Intissar Anan highlights major breakthroughs in transthyretin amyloidosis ...

Can BTK inhibitors finally move the needle in progressive MS? Dr Robert Fox joins Dr Anne Cross to unpack the results of the ...

In Huntington’s disease research, biomarkers are the secret weapon for spotting treatment effects. A new blood study uncovers two proteins, CAP1 and CAPZB, that, with additional work, could help track ...

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) announced second-quarter 2025 results and reported key advancements in ...

Clene (NASDAQ: CLNN) , a late clinical-stage biopharma company developing treatments for neurodegenerative diseases, reported Q2 2025 results and sai ...

The Company plans to hold an end-of-Phase 2 Type B meeting with the FDA in the third quarter of 2025. This meeting will review results from the Phase 2 VISIONARY-MS trial and discuss the planned Phase ...

Reports Q2 revenue $27k vs $91k last year. “We look forward to engaging with the FDA in our upcoming meeting this quarter focused on the extensive ...

A new study, published in Nature Medicine, has investigated the potential of specific biomarkers such as tau217, ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...